High flow nasal oxygen for acute type two respiratory failure: a systematic review.

ABSTRACT: Background: Acute type two respiratory failure (AT2RF) is characterized by high carbon dioxide levels (PaCO ₂ >6kPa). Non-invasive ventilation (NIV), the current standard of care, has a high failure rate. High flow nasal therapy (HFNT) has potential additional benefits such as CO ₂ clearance, the ability to communicate and comfort. The primary aim of this systematic review is to determine whether HFNT in AT2RF improves 1) PaCO ₂, 2) clinical and patient-centred outcomes and 3) to assess potential harms. Methods: We searched EMBASE, MEDLINE and CENTRAL  (January 1999-January 2021). Randomised controlled trials (RCTs) and cohort studies comparing HFNT with low flow nasal oxygen (LFO) or NIV were included. Two authors independently assessed studi

SUBMITTER: Alnajada AA 

PROVIDER: S-EPMC8453312 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature